| Code | CSB-RA007724MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ORT-247, targeting ephrin type-A receptor 4 (EPHA4), a member of the largest family of receptor tyrosine kinases. EPHA4 plays critical roles in axon guidance, neural connectivity, and synaptic plasticity during nervous system development and maintenance. Through bidirectional signaling with its ephrin ligands, EPHA4 regulates cell-cell communication, cytoskeletal dynamics, and cellular repulsion processes. Dysregulation of EPHA4 has been implicated in various pathological conditions, including amyotrophic lateral sclerosis (ALS), stroke recovery, spinal cord injury, and certain cancers where it contributes to tumor progression and metastasis.
ORT-247 represents a therapeutic antibody designed to modulate EPHA4 activity and has been investigated for its potential in neurological disorders and oncology applications. This biosimilar provides researchers with a valuable tool for investigating EPHA4-mediated signaling pathways, exploring its role in neurodegenerative diseases, studying axon regeneration mechanisms, and evaluating EPHA4 as a therapeutic target in preclinical cancer models. The antibody facilitates detailed examination of EPHA4 function across diverse biological contexts.
There are currently no reviews for this product.